Modern Brachytherapy for Treatment of Prostate Cancer

Heysek, Randy V.

doi:10.1177/107327480701400306

Cited by 28 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This drug, complexed as β-lap·HPβ-CD (ARQ 501), is currently used in clinical trials against pancreatic cancers. Currently, 10–15 year survival rates for patients with primary prostate cancer are 65% after surgery (2), and 67–87% after brachytherapy (27). Invasiveness of the surgical procedure and high local recurrence rates provide motivation for the search for efficacious alternatives and supplemental therapies.…”

Section: Discussionmentioning

confidence: 99%

Intratumoral Delivery of β-Lapachone via Polymer Implants for Prostate Cancer Therapy

Dong¹,

Chin²,

Blanco³

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: h-Lapachone (ARQ 501, a formulation of h-lapachone complexed with hydroxypropyl-h-cyclodextrin) is a novel anticancer agent with selectivity against prostate cancer cells overexpressing the NAD(P)H:quinone oxidoreductase-1enzyme. Lack of solubility and an efficient drug delivery strategy limits this compound in clinical applications. In this study, we aimed to develop h-lapachone^containing polymer implants (millirods) for direct implantation into prostate tumors to test the hypothesis that the combination of a tumor-specific anticancer agent with site-specific release of the agent will lead to significant antitumor efficacy. Experimental Design: Survival assays in vitro were used to test the killing effect of h-lapachone in different prostate cancer cells. h-Lapachone release kinetics from millirods was determined in vitro and in vivo. PC-3 prostate tumor xenografts in athymic nude mice were used for antitumor efficacy studies in vivo. Results: h-Lapachone killed three different prostate cancer cell lines in an NAD(P)H:quinone oxidoreductase-1^dependent manner. Upon incorporation of solid-state inclusion complexes of h-lapachone with hydroxypropyl-h-cyclodextrin into poly(D,L-lactide-co-glycolide) millirods, h-lapachone release kinetics in vivo showed a burst release of f0.5 mg within 12 hours and a subsequently sustained release of the drug (f0.4 mg/kg/d) comparable with that observed in vitro. Antitumor efficacy studies showed significant tumor growth inhibition by h-lapachone millirods compared with controls (P < 0.0001; n = 10 per group). Kaplan-Meier survival curves showed that tumor-bearing mice treated with h-lapachone millirods survived nearly 2-fold longer than controls, without observable systemic toxicity. Conclusions: Intratumoral delivery of h-lapachone using polymer millirods showed the promising therapeutic potential for human prostate tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Intratumoral Delivery of β-Lapachone via Polymer Implants for Prostate Cancer Therapy

Dong¹,

Chin²,

Blanco³

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Men with clinically confined prostate cancer (PCa) have numerous treatment options, including prostatectomy, external beam radiotherapy (EBRT), and permanent prostate brachytherapy (PPB) (1). Unlike EBRT and prostatectomy, the use of PPB is generally limited to patients with lowrisk disease because of lack of coverage of the immediate periprostatic tissue.…”

Section: Introductionmentioning

confidence: 99%

Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort

et al. 2015

View full text Add to dashboard Cite

“…No difference in oncological outcomes has been shown between 125 I and 103 Pd despite their different dose rates [23]. It is therefore likely that as long as the dosimetry achieved is acceptable, oncological outcomes will be similar when comparing 131 Cs, 103 Pd and 125 I.…”

Section: Discussionmentioning

confidence: 88%

Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy

Benoit¹,

Smith²,

Beriwal³

2014

Clinical Oncology

View full text Add to dashboard Cite

Modern Brachytherapy for Treatment of Prostate Cancer

Abstract: Modern-day brachytherapy utilizing either radioactive iodine-125 or palladium-103 alone or in combination with supplemental external-beam treatment offers patients a successful treatment outcome with acceptable toxicity.

Cited by 28 publications

References 38 publications

Intratumoral Delivery of β-Lapachone via Polymer Implants for Prostate Cancer Therapy

Intratumoral Delivery of β-Lapachone via Polymer Implants for Prostate Cancer Therapy

Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort

Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy

Contact Info

Product

Resources

About